{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:45:25Z","timestamp":1792842325478,"version":"4.5.0"},"posted":{"date-parts":[[2024,1,26]]},"group-title":"Neurology","reference-count":47,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,1,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>Defining the progression of blood biomarkers of Alzheimer\u2019s disease (AD) is essential for targeting treatments in patients most likely to benefit from early intervention. We delineated the temporal ordering of blood biomarkers a decade prior to the onset of AD symptoms in participants in the Baltimore Longitudinal Study of Aging. We show that increased astrocyte reactivity, assessed by elevated glial fibrillary acidic protein (GFAP) levels is an early event in the progression of blood biomarker changes in preclinical AD. In AD-converters who are initially cognitively unimpaired (N=158, 377 serial plasma samples), higher plasma GFAP levels are observed as early as 10-years prior to the onset of cognitive impairment due to incident AD compared to individuals who remain cognitively unimpaired (CU, N=160, 379 serial plasma samples). Plasma GFAP levels in AD-converters remain elevated 5-years prior to and coincident with the onset of cognitive impairment due to AD. In participants with neuropathologically confirmed AD, plasma GFAP levels are elevated relative to cognitively normal individuals and intermediate in those who remain cognitively unimpaired despite significant AD pathology (asymptomatic AD). Higher plasma GFAP levels at death are associated with greater severity of both neuritic plaques and neurofibrillary tangles. In the 5XFAD transgenic model of AD, we observed greater GFAP levels in the cortex and hippocampus of transgenic mice relative to wild-type prior to the development of cognitive impairment. Reactive astrocytosis, an established biological response to neuronal injury, may be an early initiator of AD pathogenesis and a promising therapeutic target.<\/jats:p>","DOI":"10.1101\/2024.01.25.24301779","type":"posted-content","created":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T18:25:14Z","timestamp":1706293514000},"source":"Crossref","is-referenced-by-count":15,"title":["Longitudinal progression of blood biomarkers reveals a key role of astrocyte reactivity in preclinical Alzheimer\u2019s disease"],"prefix":"10.64898","author":[{"given":"VR","family":"Varma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PR","family":"Kac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5042-7422","authenticated-orcid":false,"given":"M","family":"Bilgel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Moghekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Loeffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Amschl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Troncoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NJ","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SM","family":"Resnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Thambisetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"issue":"5","key":"2024012921050587000_2024.01.25.24301779v1.1","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","article-title":"Blood biomarkers for Alzheimer\u2019s disease in clinical practice and trials","volume":"3","year":"2023","journal-title":"Nat Aging"},{"issue":"1","key":"2024012921050587000_2024.01.25.24301779v1.2","doi-asserted-by":"crossref","first-page":"e14408","DOI":"10.15252\/emmm.202114408","article-title":"Blood-based biomarkers for Alzheimer\u2019s disease","volume":"14","year":"2022","journal-title":"EMBO molecular medicine"},{"key":"2024012921050587000_2024.01.25.24301779v1.3","unstructured":"Revised Criteria for Diagnosis and Staging of Alzheimer\u2019s Disease: Alzheimer\u2019s Association Workgroup: Alzheimer\u2019s Association; 2023 [Available from: https:\/\/aaic.alz.org\/diagnostic-criteria.asp."},{"issue":"13","key":"2024012921050587000_2024.01.25.24301779v1.4","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1001\/jama.2023.17685","article-title":"Consumers Can Now Buy a Blood Test to Evaluate Their Alzheimer Disease Risk, but Should They?","volume":"330","year":"2023","journal-title":"JAMA"},{"key":"2024012921050587000_2024.01.25.24301779v1.5","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02074-w"},{"key":"2024012921050587000_2024.01.25.24301779v1.6","doi-asserted-by":"crossref","unstructured":"Cummings J , Osse AML , Cammann D , Powell J , Chen J . Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer\u2019s Disease. BioDrugs. 2023.","DOI":"10.1007\/s40259-023-00633-2"},{"key":"2024012921050587000_2024.01.25.24301779v1.7","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12748"},{"issue":"4","key":"2024012921050587000_2024.01.25.24301779v1.8","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/alz.12724","article-title":"Plasma Abeta42\/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer\u2019s disease continuum: A cross-sectional and longitudinal study in the AIBL cohort","volume":"19","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2024012921050587000_2024.01.25.24301779v1.9","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3233\/ADR-230029","article-title":"Plasma Biomarkers of Alzheimer\u2019s Disease: A Review of Available Assays, Recent Developments, and Implications for Clinical Practice","volume":"7","year":"2023","journal-title":"J Alzheimers Dis Rep"},{"key":"2024012921050587000_2024.01.25.24301779v1.10","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12283"},{"issue":"4","key":"2024012921050587000_2024.01.25.24301779v1.11","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jamaneurol.2022.5272","article-title":"Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers","volume":"80","year":"2023","journal-title":"JAMA Neurol"},{"key":"2024012921050587000_2024.01.25.24301779v1.12","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30071-5"},{"issue":"5","key":"2024012921050587000_2024.01.25.24301779v1.13","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","article-title":"Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology","volume":"141","year":"2021","journal-title":"Acta neuropathologica"},{"issue":"10","key":"2024012921050587000_2024.01.25.24301779v1.14","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1002\/alz.13157","article-title":"Longitudinal changes in Alzheimer\u2019s-related plasma biomarkers and brain amyloid","volume":"19","year":"2023","journal-title":"Alzheimers Dement"},{"key":"2024012921050587000_2024.01.25.24301779v1.15","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-020-02195-x"},{"issue":"1","key":"2024012921050587000_2024.01.25.24301779v1.16","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40478-018-0649-3","article-title":"Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration","volume":"7","year":"2019","journal-title":"Acta Neuropathol Commun"},{"issue":"12","key":"2024012921050587000_2024.01.25.24301779v1.17","first-page":"1416","article-title":"The Baltimore Longitudinal Study of Aging (BLSA): a 50-year-long journey and plans for the future","volume":"63","year":"2008","journal-title":"The journals of gerontology"},{"key":"2024012921050587000_2024.01.25.24301779v1.18","unstructured":"Shock NW , Gruelich R , Andres R , Arenberg D , Costa PT , Lakatta EG , et al. Normal Human Aging: The Baltimore Longitudinal Study of Aging. Washington, DC, USA: U.S. Government Printing Office; 1984."},{"issue":"3","key":"2024012921050587000_2024.01.25.24301779v1.19","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3233\/JAD-2009-1179","article-title":"Neuropathologic studies of the Baltimore Longitudinal Study of Aging (BLSA)","volume":"18","year":"2009","journal-title":"Journal of Alzheimer\u2019s disease : JAD"},{"key":"2024012921050587000_2024.01.25.24301779v1.20","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.11.2072"},{"key":"2024012921050587000_2024.01.25.24301779v1.21","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21413"},{"key":"2024012921050587000_2024.01.25.24301779v1.22","doi-asserted-by":"publisher","DOI":"10.1097\/NEN.0000000000000052"},{"key":"2024012921050587000_2024.01.25.24301779v1.23","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-2275(20)43176-1"},{"key":"2024012921050587000_2024.01.25.24301779v1.24","doi-asserted-by":"publisher","DOI":"10.1515\/CCLM.2002.197"},{"key":"2024012921050587000_2024.01.25.24301779v1.25","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1202-06.2006"},{"issue":"1","key":"2024012921050587000_2024.01.25.24301779v1.26","doi-asserted-by":"crossref","first-page":"e1002482","DOI":"10.1371\/journal.pmed.1002482","article-title":"Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study","volume":"15","year":"2018","journal-title":"PLoS Med"},{"key":"2024012921050587000_2024.01.25.24301779v1.27","doi-asserted-by":"crossref","first-page":"103837","DOI":"10.1016\/j.ebiom.2022.103837","article-title":"Comparing tau status determined via plasma pTau181, pTau231 and [(18)F]MK6240 tau-PET","volume":"76","year":"2022","journal-title":"EBioMedicine"},{"issue":"1","key":"2024012921050587000_2024.01.25.24301779v1.28","first-page":"34","article-title":"Plasma Abeta42\/40 Ratio Detects Early Stages of Alzheimer\u2019s Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study","volume":"6","year":"2019","journal-title":"The journal of prevention of Alzheimer\u2019s disease"},{"key":"2024012921050587000_2024.01.25.24301779v1.29","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(06)70501-4"},{"key":"2024012921050587000_2024.01.25.24301779v1.30","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.34.7.939"},{"key":"2024012921050587000_2024.01.25.24301779v1.31","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.56.3.303"},{"key":"2024012921050587000_2024.01.25.24301779v1.32","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.41.4.479"},{"key":"2024012921050587000_2024.01.25.24301779v1.33","doi-asserted-by":"publisher","DOI":"10.1007\/BF00308809"},{"key":"2024012921050587000_2024.01.25.24301779v1.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2017.06.006"},{"key":"2024012921050587000_2024.01.25.24301779v1.35","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12131"},{"issue":"1","key":"2024012921050587000_2024.01.25.24301779v1.36","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s40478-022-01370-3","article-title":"Changes in glial cell phenotypes precede overt neurofibrillary tangle formation, correlate with markers of cortical cell damage, and predict cognitive status of individuals at Braak III-IV stages","volume":"10","year":"2022","journal-title":"Acta Neuropathol Commun"},{"issue":"7","key":"2024012921050587000_2024.01.25.24301779v1.37","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1038\/s41591-023-02380-x","article-title":"Astrocyte reactivity influences amyloid-beta effects on tau pathology in preclinical Alzheimer\u2019s disease","volume":"29","year":"2023","journal-title":"Nature medicine"},{"key":"2024012921050587000_2024.01.25.24301779v1.38","doi-asserted-by":"crossref","unstructured":"Reichenbach N , Delekate A , Plescher M , Schmitt F , Krauss S , Blank N , et al. Inhibition of Stat3-mediated astrogliosis ameliorates pathology in an Alzheimer\u2019s disease model. EMBO molecular medicine. 2019;11(2).","DOI":"10.15252\/emmm.201809665"},{"key":"2024012921050587000_2024.01.25.24301779v1.39","first-page":"1759091420949680","article-title":"GFAP at 50","volume":"12","year":"2020","journal-title":"ASN Neuro"},{"issue":"46","key":"2024012921050587000_2024.01.25.24301779v1.40","doi-asserted-by":"crossref","first-page":"eabi8178","DOI":"10.1126\/sciadv.abi8178","article-title":"A brain proteomic signature of incipient Alzheimer\u2019s disease in young APOE epsilon4 carriers identifies novel drug targets","volume":"7","year":"2021","journal-title":"Sci Adv"},{"issue":"3","key":"2024012921050587000_2024.01.25.24301779v1.41","first-page":"158","article-title":"Blood GFAP as an emerging biomarker in brain and spinal cord disorders","volume":"18","year":"2022","journal-title":"Nature reviews"},{"issue":"4","key":"2024012921050587000_2024.01.25.24301779v1.42","doi-asserted-by":"crossref","first-page":"e12794","DOI":"10.1111\/gbb.12794","article-title":"Visuo-spatial learning and memory impairments in the 5xFAD mouse model of Alzheimer\u2019s disease: Effects of age, sex, albinism, and motor impairments","volume":"21","year":"2022","journal-title":"Genes Brain Behav"},{"issue":"1","key":"2024012921050587000_2024.01.25.24301779v1.43","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13024-023-00647-y","article-title":"Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer\u2019s disease with multi-modal PET and plasma GFAP","volume":"18","year":"2023","journal-title":"Molecular neurodegeneration"},{"key":"2024012921050587000_2024.01.25.24301779v1.44","doi-asserted-by":"publisher","DOI":"10.1093\/jnen\/60.5.449"},{"issue":"11","key":"2024012921050587000_2024.01.25.24301779v1.45","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1001\/jamaneurol.2021.3180","article-title":"Head-to-Head Comparison of 8 Plasma Amyloid-beta 42\/40 Assays in Alzheimer Disease","volume":"78","year":"2021","journal-title":"JAMA Neurol"},{"key":"2024012921050587000_2024.01.25.24301779v1.46","doi-asserted-by":"publisher","DOI":"10.1089\/neu.2015.4333"},{"issue":"3","key":"2024012921050587000_2024.01.25.24301779v1.47","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1038\/s41380-022-01912-0","article-title":"Hydroxychloroquine lowers Alzheimer\u2019s disease and related dementias risk and rescues molecular phenotypes related to Alzheimer\u2019s disease","volume":"28","year":"2023","journal-title":"Molecular psychiatry"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2024.01.25.24301779","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T19:49:42Z","timestamp":1768506582000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2024.01.25.24301779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,26]]},"references-count":47,"URL":"https:\/\/doi.org\/10.1101\/2024.01.25.24301779","relation":{},"subject":[],"published":{"date-parts":[[2024,1,26]]},"subtype":"preprint"}}